. 2011 Dec;24(6):463–469. doi: 10.1089/vim.2011.0039

Table 2.

Antibody Titers (Median Reciprocal ID₅₀)^a with Respect to Different Clinical Parameters

	V3C		IDL		MPER
Peptide	Naive	Treated	Naive	Treated	Naive	Treated
Overall titers (40 N, 35 T)^b	6550	1300	2050	250	100	100
Clinical stage
Stage 1/T1 (24 N, 29 T)	7150	1150	2225	250	100	100
Stage 2,3/T2,3 (16 N, 6 T)	5713	2250	1675	1275	138	125
Age
<5 years (13 N, 2 T)	6825	1125^c	2500	400	100	250
≥5 years (27 N, 33 T)	5250	1300	1700	250	100	100
CD4 count^d
<350 cells/μL (4 N, 9 T)	7213	2900	5250	900	550	100
≥350 cells/μL (20 N, 22 T)	6175	1100	1725	225	100	100
Viral load
<47 RNA copies/mL (9 N, 8 T)	6175	550	2300	250	100	100
>47 RNA copies/ml (21 N, 16 T)	7100	2075	2150	400	100	100

^{^a}

Median reciprocal ID₅₀ titers were calculated from individual ID₅₀ titers of each patient in the respective groups. Individual ID₅₀ titers of the plasma samples whose values were less than 100 (more than three times the lowest dilution tested 1:30) were assigned a value of 100, and then the median reciprocal ID₅₀ titers were calculated for each subgroup.

^{^b}

Numbers in parentheses represent the number of children analyzed in each group (N=naive; T=treated).

^{^c}

Those with italicized and underlined numbers represent mean ID₅₀ titers in the respective groups.

^{^d}

Children <5 y of age and for whom CD4 count was unavailable were excluded from the analysis.

ID₅₀, inhibitory dilution at 50% binding.